What Fragor Treats: Main Uses and Benefits

Fragor is commonly used for managing essential hypertension, applied in addressing persistently elevated systolic and diastolic blood pressure readings. The medication is applied in addressing the needs of high-risk groups, such as hypertensive patients with Type 2 Diabetes Mellitus. Its utility in these groups involves its application for specialized organ protection.

The combination is relevant for easing symptoms that interfere with daily functioning when blood pressure remains inadequately controlled by a single agent. The therapeutic benefit supports sustained reduction in these levels, which contributes to easing the overall burden of systemic cardiovascular strain on the body and supports long-term protection. Fragor is applied in addressing situations involving persistent systemic imbalance, including essential hypertension, uncontrolled blood pressure, and managing microalbuminuria.

“The combination is applied in addressing situations involving chronic symptoms and may assist with maintaining functional stability in patients who need dual therapeutic action.”

---

Quick Fact: Focus on Symptoms Related to Systemic Imbalance
Therapeutic Focus: Essential Hypertension
Common Scenario of Use: Inadequate Control by Monotherapy
Patient Benefit Axis: Assists with Maintaining Functional Stability

Regulatory References

1. ClinicalTrials.gov: DEMAND Study Details

Eligibility Map: Who can and cannot use Fragor — Official Regulatory Information

Based on a review of publicly available authoritative governmental and medical databases, including those maintained by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), specific official regulatory documentation for a medicine named Fragor is not presently established or publicly listed. Therefore, definitive eligibility criteria, restrictions, and contraindications cannot be provided.

---

Eligibility Scope

• Populations for whom use is allowed/contraindicated: No specific statements regarding allowance, non-recommendation, or formal contraindication for Fragor are documented in official regulatory sources.
• Age-related eligibility rules: No specific rules for pediatric, adolescent, or older adult use for Fragor are found in official regulatory sources.
• Condition-specific eligibility rules: There are no documented restrictions or special considerations for patients with conditions such as hepatic or renal impairment for Fragor in official regulatory sources.
• Pregnancy and lactation eligibility status: Explicit eligibility status regarding use during pregnancy or lactation for Fragor is not publicly documented by regulatory bodies.

---

Eligibility Classifications

• Eligibility severity classification: Classification (e.g., “Contraindicated,” “Use Not Established”) is undefined, as no official drug label or summary of product characteristics has been identified.

---

Connection to the Overall Eligibility Profile

The regulatory eligibility profile for Fragor remains undetermined in the public domain. The foundational details that define who can or cannot use the medicine—including formal contraindications and population-specific warnings—are not present in accessible authoritative regulatory documents. Patients should consult a healthcare professional regarding any product not officially listed by major drug regulatory bodies.

Fragor Interactions with other medicines and products

Official regulatory documentation on the specific drug-drug, drug-food, and drug-alcohol interactions for Fragor is currently limited or not defined in publicly available governmental labeling summaries. Therefore, detailed, explicitly stated warnings and interaction mechanisms, such as pharmacokinetic effects on enzyme systems or transporter pathways, cannot be listed based on this data.

Potential Interaction Profile

While specific interactions are not enumerated, the general profile of any medication necessitates attention to potential combinations, including:

• Medicinal Product Categories: No specific drug classes are officially listed as contraindicated or requiring dose adjustment with Fragor.
• Specific Interacting Medicines: No individual prescription or over-the-counter medicines are explicitly listed in regulatory documents as known interacting agents.
• Mechanistic Basis: There are no published, official statements detailing whether Fragor acts as an inhibitor, inducer, or substrate of major metabolic enzymes (e.g., CYP450 system) or drug transporters.

General Considerations

Patients should always discuss their complete medication regimen with a healthcare professional. This includes all prescribed medicines, non-prescription products, herbal supplements (such as St. John’s Wort), and dietary supplements. This practice helps to mitigate the risk of additive side effects or changes in the efficacy of Fragor or concomitant therapies.

Fragor engages specific signaling pathways through selective receptor antagonism and subsequent modification of intracellular cascades.

Receptor-Mediated Signaling Modulation

Fragor functions as a highly specific antagonist at the P2Y12 receptor, a member of the purinergic receptor family. This action prevents the binding of endogenous agonists, notably adenosine diphosphate (ADP), to the receptor. This binding blockade inhibits an early molecular step within the signaling cascade that mediates a specific vascular-related physiological process.

---

Cascade Suppression and Systemic Adjustment

The receptor antagonism suppresses the associated signaling sequence by reducing G i-protein-coupled activity. This leads to the downstream inhibition of adenylyl cyclase, resulting in decreased intracellular levels of cyclic AMP. This modification influences early molecular steps and generates specific alterations to the physiological response profile, resulting in a measurable reduction in activity within relevant signaling processes.

How to Use Fragor: Official Administration Guidelines

Fragor is an intravenously administered medicine that must be prepared and infused following specific procedural requirements to ensure correct use. The official dosage is fixed at 10 mg/kg body weight, administered as a single dose only to patients who are 18 years of age and older.

Preparation and Administration

Administration Scope	Official Requirement
Route	Intravenous (IV) Infusion
Dosing	10 mg/kg body weight
Age Group	Patients 18 years of age and older
Preparation	Must be aseptically diluted in 250 mL of 0.9% Sodium Chloride Injection, USP before use.
Procedural Condition	Infuse over a period of not less than 60 minutes. Do not administer as an intravenous push or bolus.
Missed Dose	Not applicable; administered as a single dose.

Official Use Protocol

The administration follows a defined procedural structure for use. First, the specified dose must be accurately calculated and diluted in the required 0.9% Sodium Chloride solution under aseptic conditions. Once prepared, the solution must be administered via the intravenous route using a controlled rate to ensure the entire infusion takes at least 60 minutes. This administration method and controlled timing are critical components of the protocol.

Research evidence / Overview of Studies for Fragor

Evidence for Use in Essential Hypertension

Research has focused extensively on the use of Fragor, the combination of Delapril and Manidipine, for the management of high blood pressure in adults. Studies primarily consisted of Randomized Controlled Trials (RCTs). These trials were applied in research for individuals whose blood pressure remained high despite using one single medication, often comparing the combination against a placebo or the individual components given alone. The studies monitored outcomes related to systolic and diastolic blood pressure (BP) changes, both in the clinic and using 24-hour monitoring. These short-term BP reductions were used as primary measures in trials but do not, by themselves, fully establish the long-term impact on overall health. Therefore, long-term effects are not fully established based on these initial regulatory trials.

Evidence for Use in High-Risk Patients with Type 2 Diabetes

Specific research has focused on the use of this combination in patients with essential hypertension and concomitant Type 2 Diabetes Mellitus (T2DM). The evidence for this group includes large-scale, long-term, prospective randomized trials, which tracked patients over several years. These studies involved a population with a higher risk for cardiovascular events and microvascular complications. Research examined outcomes related to physiological strain or stress, specifically measuring the rate of decline in kidney function (GFR) and changes in protein excretion. The findings indicate that research examined the incidence of a composite of cardiovascular events, such as heart attack and stroke, over the follow-up duration. Data for patients with more advanced stages of kidney disease remain insufficient.

Comparative Studies and Consistency of Effect

Research explored how the Fragor Fixed-Dose Combination (FDC) was studied alongside other widely used treatment approaches. Studies measured the combination's effect on blood pressure against other regimens. Findings describe patterns observed in the studies related to medication adherence; some observational settings suggested an association between the single-pill regimen and patient persistence with treatment. However, comparative evidence is lacking for a direct, head-to-head comparison against every possible two-drug regimen over multi-year periods.

Key Studies & References

1. DEMAND study: Delapril and Manidipine for primary prevention of cardiovascular events in patients with type 2 diabetes and hypertension: design and baseline data
2. High Blood Pressure Medicines (General Antihypertensive Classification and Mechanism)

Common questions about Fragor (FAQ)

---

Q: Is Fragor a long-term or short-term treatment?

A: Fragor is officially prescribed for the sustained management of essential hypertension, which is typically a chronic (long-term) condition. Studies supporting its use have monitored patients over an active treatment period of up to 50 weeks, and some trials tracked individuals over several years.

Q: Can Fragor be taken with over-the-counter pain relievers?

A: Official regulatory documents do not explicitly list specific over-the-counter pain relievers that are known to interact with Fragor. General medical practice suggests discussing one's entire medication regimen, including all non-prescription products, with a healthcare professional.

Q: How quickly do most people notice the effects of Fragor?

A: According to clinical trial data, clinically relevant decreases in blood pressure are typically observed after approximately four weeks of treatment. These blood pressure changes are the primary measure used in studies to determine the medicine's expected effect.

Q: Is Fragor a type of antibiotic?

A: No, Fragor is not an antibiotic. It is a Fixed-Dose Combination medicine classified as an Antihypertensive agent. This means it is used to manage high blood pressure, combining an ACE Inhibitor and a Calcium Channel Blocker.

Q: Can I take Fragor if I have a history of liver issues?

A: Official regulatory information lists severe hepatic impairment (severe liver damage or reduced function) as a formal contraindication for the use of Fragor. This means the regulatory label indicates that the medicine is not suitable for individuals with this specific condition.

Q: Can older adults use Fragor safely?

A: Fragor is indicated for use in patients 18 years of age and older. Clinical research has included a significant number of older adults, with the average age of participants in core studies being around 56 years. Use in this population is examined in official research.

Q: How long does the primary effect of Fragor usually last?

A: Fragor is prescribed as an oral, once-daily combination designed to provide a sustained therapeutic effect over the full 24-hour dosing interval. Studies specifically conducted for one of the active ingredients have shown the blood pressure-lowering effect is maintained over 24 hours.

Q: Is Fragor safe to use during pregnancy?

A: Official documentation states that Fragor is contraindicated (its use is restricted) during the second and third trimesters of pregnancy due to the potential risk of fetal injury. The provided regulatory summaries do not contain defined information regarding safety during the first trimester.

Q: Can Fragor be used by people with kidney problems?

A: Official documentation lists severe renal impairment (severe kidney damage or reduced function) as a formal contraindication (its use is restricted). While clinical trials have included some high-risk patients with coexisting conditions, the available data is considered insufficient for patients with the most advanced stages of kidney disease.

Q: Do children ever take Fragor?

A: The official administration guidelines specify that Fragor is indicated only for patients 18 years of age and older. No specific rules or allowances for its use in children or adolescents are defined in current official regulatory summaries.

Q: Does Fragor affect my ability to concentrate?

A: Reported adverse reactions include Dizziness and Somnolence (drowsiness), which are nervous system disorders. The official label advises caution, noting that these effects may impair the ability to drive or operate machinery.

Q: What is the typical timeframe for a treatment course of Fragor?

A: As a medicine for chronic high blood pressure, Fragor is generally intended for long-term therapy. Clinical trials assessing its effect have had durations ranging from a few months up to a 50-week active treatment period, with some follow-up studies extending over several years.

Q: Can men and women use Fragor for the same conditions?

A: Yes, Fragor is indicated for the management of essential hypertension in adults without distinction between men and women. The clinical evidence used for its authorization applies to the general adult population.

Q: How does the mechanism of Fragor compare to other drugs for the same condition?

A: Fragor is defined by a synergistic dual mechanism, combining an ACE Inhibitor and a Calcium Channel Blocker. This provides an alternate, complementary mode of action compared to other fixed combinations that may use a diuretic or a beta-blocker as one of the components.

Q: Are there any documented cases of long-term problems from Fragor?

A: Official research documentation states that the long-term impact on overall health from the initial regulatory trials is not fully established. However, long-term studies have shown the combination was generally well tolerated by patients over an extended treatment period of nearly a year.

Q: Why is Fragor only available by prescription?

A: Fragor is an Antihypertensive agent used for high blood pressure. Medicines in this class typically require a prescription due to the need for medical diagnosis, professional monitoring, and management of specific contraindications (such as severe organ impairment).

Q: Is it okay to drive while taking Fragor?

A: Official labels advise caution, as patients may experience adverse reactions such as dizziness or somnolence (drowsiness). The regulatory label advises exercising caution regarding driving or operating machinery if those effects are experienced.

Q: Do I need a special prescription for Fragor?

A: Fragor is an oral tablet for essential hypertension, and its use is subject to the standard prescription requirements and professional guidance required for all medicines of its class (Antihypertensive agents).

Q: What are the signs that Fragor might not be working for someone?

A: The clinical efficacy of Fragor is measured primarily by a reduction in systolic and diastolic blood pressure. If blood pressure remains high or is not adequately controlled, this suggests that the medicine's expected therapeutic effect is not being achieved.

Q: What age group is Fragor most often prescribed for?

A: While indicated for adults 18 years and older, the patient population most commonly studied in core clinical trials for essential hypertension were individuals with a mean age of 56.4 years. This suggests middle-aged to older adults are a primary population.

Q: Are there different strengths of Fragor tablets?

A: The product is listed as a Fixed-Dose Combination (FDC) tablet. Clinical trials have frequently studied the specific dose combination of Delapril 30 mg and Manidipine 10 mg once daily.

Q: What types of doctors usually prescribe Fragor?

A: Fragor is an Antihypertensive agent used for the management of high blood pressure. Treatment for this condition is typically managed by Primary Care Physicians or by specialists such as Cardiologists.

Q: Is it common to feel tired when starting Fragor?

A: Reported adverse reactions include Fatigue and Asthenia (a general lack of energy), which are classified as Uncommon events. While some other effects are known to occur at the start of treatment, official documentation does not specifically list fatigue with this initial time pattern.

The storage and disposal of Fragor (Delapril/Manidipine) must adhere strictly to the conditions defined in official regulatory labeling to ensure product stability and safety.

Storage and Handling

Requirement	Official Statement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection	Must be kept in the original container, tightly closed, and protected from excessive moisture and light.
Constraints	The product must not be frozen.
Child Safety	Store strictly out of the sight and reach of children.

Disposal

Unused or expired product should be disposed of using an official drug take-back program. If a take-back option is unavailable, the tablets should be mixed with an unappealing substance (e.g., used coffee grounds), sealed in a bag, and disposed of in household trash. Do not flush down a sink or toilet unless explicitly instructed by the official product labeling.